|
|
|
| Obesity Tx End-Around With Skye Bioscience's Punit Dhillon | While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant, Skye Bioscience CEO Punit Dhillon is confident that their antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics. |
|
|
|
|
By Yadnyesh Patel, microbiology subject matter expert | Sterility assurance is a critical aspect of the production of drugs and medical devices. This article covers the fundamentals, including the key components of an effective sterility assurance program. |
|
|
|
| Overcoming Challenges In CGT Development | Webinar | CPC | Explore connector solutions for sterility, chemical compatibility, and ultra-low temperature challenges when setting up a therapeutic process for long-term success. |
|
|
| Standardization And Flexibility In Aseptic Filling | Article | Cytiva | Standardization and flexibility in aseptic filling were thought to be mutually exclusive. But what if there was a standardized system with flexibility built into the aseptic process, so you didn’t have to choose? |
|
|
|
|
| Key Considerations For Selecting Flexible Fillers | Article | West Pharmaceutical Services, Inc. | Flexible fillers are beneficial to drug developers looking for lifecycle management of their drug products. Explore key considerations for selecting flexible fill/finish manufacturing technologies. |
|
|
|
|
|
|
|
By Matt Campasano, Criterion Consulting LLC | Industry still struggles to manage complex data requirements, which forced the FDA to once again delay enforcement of the Drug Supply Chain Security Act. |
|
|
| Managing Supply For Complex Biotherapeutics | Article | By Iwan Bertholjotti, Lonza | Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill & finish. |
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
.png)
